Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology

No abstract is available for this paper.

• Publication year

  2019

• Venue

  International Journal of Clinical Oncology

• Publication date

  2019-08-12

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s10147-019-01520-zPMID 31407168
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Re: Molecular Subtype-Specific Immunocompetent Models of High-Grade Urothelial Carcinoma Reveal Differential Neoantigen Expression and Response to Immunotherapy.

  2020influential reference
• Personalized Dendritic Cell Vaccines—Recent Breakthroughs and Encouraging Clinical Results

  2019cited by this paper
• Modelling cancer in microfluidic human organs-on-chips

  2019cited by this paper
• A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy

  2019cited by this paper
• Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts

  2019cited by this paper
• Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.

  2019cited by this paper
• Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data

  2019cited by this paper
• The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability.

  2019cited by this paper
• Molecular Subtype-Specific Immunocompetent Models of High-Grade Urothelial Carcinoma Reveal Differential Neoantigen Expression and Response to Immunotherapy.

  2018cited by this paper
• Mouse strain and sex as determinants of immune response to trivalent influenza vaccine

  2018cited by this paper
• Cell Line Models of Molecular Subtypes of Colorectal Cancer.

  2018cited by this paper
• The Immune Landscape of Cancer.

  2018cited by this paper
• The Use of the Humanized Mouse Model in Gene Therapy and Immunotherapy for HIV and Cancer

  2018cited by this paper
• Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

  2018cited by this paper
• Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

  2018cited by this paper
• Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

  2018cited by this paper
• Histological subtypes of mouse mammary tumors reveal conserved relationships to human cancers

  2018cited by this paper
• Tissue-resident memory CD8+ T cells promote melanoma–immune equilibrium in skin

  2018cited by this paper
• Organoid Modeling of the Tumor Immune Microenvironment.

  2018cited by this paper
• Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy.

  2018cited by this paper
• Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors

  2018cited by this paper
• Towards the development of human immune-system-on-a-chip platforms

  2018cited by this paper
• Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids.

  2018cited by this paper
• Mutational landscape of a chemically-induced mouse model of liver cancer

  2018cited by this paper
• Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.

  2017cited by this paper
• Patient-derived xenografts as in vivo models for research in urological malignancies

  2017cited by this paper
• Identification of CMTM6 and CMTM4 as PD-L1 protein regulators

  2017cited by this paper
• Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.

  2017cited by this paper
• Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

  2017cited by this paper
• Making Mouse Models That Reflect Human Immune Responses.

  2017cited by this paper
• CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity

  2017cited by this paper
• Ethics of animal research in human disease remediation, its institutional teaching; and alternatives to animal experimentation

  2017cited by this paper
• An Immunogram for the Cancer‐Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer

  2017cited by this paper
• Mouse models of metastasis: progress and prospects

  2017cited by this paper
• Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy

  2016cited by this paper
• Adapting Cancer Immunotherapy Models for the Real World.

  2016cited by this paper
• Claudin-low bladder tumors are immune infiltrated and actively immune suppressed.

  2016cited by this paper
• Sequential Infection with Common Pathogens Promotes Human-like Immune Gene Expression and Altered Vaccine Response.

  2016cited by this paper
• Does age matter? The impact of rodent age on study outcomes

  2016cited by this paper
• Mouse models in oncoimmunology

  2016influential reference
• Genetically engineered mouse models in oncology research and cancer medicine

  2016cited by this paper
• Mouse Models of Tumor Immunotherapy.

  2016cited by this paper
• PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

  2016cited by this paper
• Recapitulating adult human immune traits in laboratory mice by normalizing environment

  2016cited by this paper
• Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse

  2016cited by this paper
• Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies.

  2016cited by this paper
• Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

  2015cited by this paper
• Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy

  2015cited by this paper
• Animal Models of Chemical Carcinogenesis: Driving Breakthroughs in Cancer Research for 100 Years.

  2015cited by this paper
• Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis.

  2015cited by this paper
• Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice.

  2015cited by this paper
• Precision cancer mouse models through genome editing with CRISPR-Cas9

  2015cited by this paper
• Preclinical mouse cancer models: a maze of opportunities and challenges.

  2015cited by this paper
• Clinical impact of H-Y alloimmunity

  2014cited by this paper
• Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma

  2014cited by this paper
• Modelling bladder cancer in mice: opportunities and challenges

  2014influential reference
• In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system

  2014cited by this paper
• Development and function of human innate immune cells in a humanized mouse model

  2014influential reference
• Downregulation of Ral GTPase-activating protein promotes tumor invasion and metastasis of bladder cancer

  2013influential reference
• Causes, consequences, and reversal of immune system aging.

  2013cited by this paper
• The evolutionary basis for differences between the immune systems of man, mouse, pig and ruminants.

  2013cited by this paper
• Humanized mice for immune system investigation: progress, promise and challenges

  2012cited by this paper
• Abstract 526: Cancer immunoediting by the innate immune system in the absence of adaptive immunity

  2012cited by this paper
• A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth

  2012influential reference
• Immunological Variation Between Inbred Laboratory Mouse Strains

  2012influential reference
• Cancer immunoediting by the innate immune system in the absence of adaptive immunity

  2012cited by this paper
• Mouse models of advanced spontaneous metastasis for experimental therapeutics

  2011cited by this paper
• Natural innate and adaptive immunity to cancer.

  2011cited by this paper
• Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2Rγ(null) humanized mice.

  2011cited by this paper
• The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies

  2011cited by this paper
• Systems biology and genomics of breast cancer.

  2011cited by this paper
• Tumor Immunoediting by NKp46

  2010cited by this paper
• Origin and evolution of the adaptive immune system: genetic events and selective pressures

  2010cited by this paper
• Increased Susceptibility to Skin Carcinogenesis in TREX2 Knockout Mice.

  2009cited by this paper
• Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis

  2008cited by this paper
• PD-1 and PD-1 ligands: from discovery to clinical application.

  2007cited by this paper
• Using Genetically Engineered Mouse Models of Cancer to Aid Drug Development: An Industry Perspective

  2006cited by this paper
• The mighty mouse: genetically engineered mouse models in cancer drug development

  2006cited by this paper
• Unique Tumor Antigens: Evidence for Immune Control of Genome Integrity and Immunogenic Targets for T Cell–Mediated Patient-Specific Immunotherapy

  2006cited by this paper
• Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies.

  2005cited by this paper
• PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells.

  2004cited by this paper
• Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

  2002cited by this paper
• Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

  2001cited by this paper
• IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity

  2001cited by this paper
• Faculty Opinions recommendation of IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.

  2001cited by this paper
• The makings of a tumor rejection antigen.

  1999cited by this paper
• Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC

  1997cited by this paper
• Enhancement of Antitumor Immunity by CTLA-4 Blockade

  1996cited by this paper
• Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

  1992cited by this paper
• Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo.

  1987cited by this paper
• Antigenicity of murine skin tumors induced by ultraviolet light.

  1974cited by this paper
• Immunity to methylcholanthrene-induced sarcomas.

  1957cited by this paper

• Ferroptosis as a Novel Therapeutic Strategy to Overcome Multidrug Resistance in Colorectal Cancer.

  2026cites this paper
• Clinical complete response achieved in patients with breast cancer liver metastasis after personalized treatment: a case report and literature review

  2026cites this paper
• Integrating AI, Machine Learning, and Animal Models for Precision Oncology: Bridging Preclinical and Clinical Gaps.

  2025cites this paper
• Head and neck cancer organoids: a panoramic perspective from basic construction to clinical translation

  2025cites this paper
• Effects of aging on anticancer therapy in murine cancer models

  2025cites this paper
• Lung Cancer Organoids in Translational Research: Bridging Basic Science, Drug Development, and Clinical Therapeutics.

  2025cites this paper
• Animal Models: A Tool for Colon Cancer Research

  2025cites this paper
• Translationale Forschung in der Radioonkologie

  2025cites this paper
• A New Perspective on Precision Medicine: The Power of Digital Organoids

  2025cites this paper
• Combination of tumor organoids with advanced technologies: A powerful platform for tumor evolution and treatment response (Review)

  2025cites this paper
• Development and Application of Tumor Organoids: An Emerging Platform for Gynecological Cancers

  2025cites this paper
• Emerging In Vitro and In Vivo Models: Hope for the Better Understanding of Cancer Progression and Treatment

  2024cites this paper
• Exploratory Insights from the Immuno-Oncology Hollow Fiber Assay: A Pilot Approach Bridging In Vitro and In Vivo Models.

  2024cites this paper
• SOAT1 in gallbladder cancer: Clinicopathological significance and avasimibe therapeutics

  2024cites this paper
• Towards effective CAIX-targeted radionuclide and checkpoint inhibition combination therapy for advanced clear cell renal cell carcinoma

  2024cites this paper
• Current approaches to quality assessment, non-clinical and clinical studies of dendritic cell vaccines in oncology

  2023cites this paper
• The advent of immune stimulating CAFs in cancer

  2023cites this paper
• Review of Malaysian Medicinal Plants with Potential Anticancer Activity

  2023cites this paper
• Establishment of an orthotopic model of lung cancer by transthoracic lung puncture using tumor fragments

  2023cites this paper
• Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance

  2023cites this paper
• Flourishing tumor organoids: History, emerging technology, and application

  2023cites this paper
• A Review of Malaysian Medicinal Plants with Potential Anticancer Activity

  2023cites this paper
• Modeling of multiple primary malignant tumors in experiment

  2022cites this paper
• Intravesical VAX014 Synergizes with PD-L1 Blockade to Enhance Local and Systemic Control of Bladder Cancer

  2022cites this paper
• Biomarkers and 3D models predicting response to immune checkpoint blockade in head and neck cancer (Review)

  2022cites this paper
• Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model

  2022cites this paper
• Sources of inter-individual variability leading to significant changes in anti-PD-1 and anti-PD-L1 efficacy identified in mouse tumor models using a QSP framework

  2022cites this paper
• Evaluating Translational Methods for Personalized Medicine—A Scoping Review

  2022cites this paper
• Novel non-terminal tumor sampling procedure using fine needle aspiration supports immuno-oncology biomarker discovery in preclinical mouse models

  2021cites this paper
• Interrogating preclinical study of liposomes: The effect of mouse strain reexamined.

  2021cites this paper
• Combination Therapy of Novel Oncolytic Adenovirus with Anti-PD1 Resulted in Enhanced Anti-Cancer Effect in Syngeneic Immunocompetent Melanoma Mouse Model

  2021cites this paper
• Modeling human tumor-immune environments in vivo for the preclinical assessment of immunotherapies

  2021cites this paper
• Preclinical Solid Tumor Models to Study Novel Therapeutics in Brain Metastases

  2021cites this paper
• Human CD22-Transgenic, Primary Murine Lymphoma Challenges Immunotherapies in Organ-Specific Tumor Microenvironments

  2021cites this paper
• Current research developments of patient-derived tumour xenograft models (Review).

  2021cites this paper
• Preclinical models in oncological pharmacology: limits and advantages

  2021cites this paper
• Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme.

  2021cites this paper
• Divergent immune landscapes of primary and syngeneic Kras-driven mouse tumor models

  2021cites this paper
• Patient-Derived Urothelial Cancer Xenograft Models: A Systematic Review and Future Perspectives

  2020cites this paper
• From Cancer to Immune-Mediated Diseases and Tolerance Induction: Lessons Learned From Immune Oncology and Classical Anti-cancer Treatment

  2020cites this paper
• OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors

  2020cites this paper
• The humanized mouse: Emerging translational potential

  2020cites this paper
• New murine models of aggressive lymphoma

  2019cites this paper